This webinar introduces key updates in acute ischemic stroke management, focusing on how modern decision‑making integrates time‑sensitive evaluation, advanced imaging, and AI‑supported tools. It also reviews the expanded…
Daniel R. Schimmel, MD, explains how balloon pulmonary angioplasty (BPA) uses balloons and specialized catheters to open narrowed vessels in the lungs to improve circulation and reduce symptoms…
NEW YORK (Reuters Health) – It makes no difference whether internal tocodynamometry or external monitoring is used during induced or augmented labor – either way, the rate of…
NEW YORK (Reuters Health) – When paroxysmal atrial fibrillation has not responded to at least one antiarrhythmic agent, radiofrequency catheter ablation is more effective at preventing further episodes…
NEW YORK (Reuters Health) – Prompt treatment of subclinical and clinical seizures in newborns with hypoxic-ischemic encephalopathy (HIE) can potentially decrease brain injury, according to a prospective trial…
NEW YORK (Reuters Health) – High-dose atorvastatin does not protect against contrast-induced nephropathy (CIN) in patients with kidney disease, Italian researchers report. “Statins have recently been proposed for…
NEW YORK (Reuters Health) – The biomarker procalcitonin can help guide treatment of severe bacterial infections in the intensive care unit (ICU), French investigators report online in The…
NEW YORK (Reuters Health) – Endovascular treatment of intracranial aneurysms 3 mm or smaller in diameter is difficult and risky — but it’s successful in over 90% of…
NEW YORK (Reuters Health) – Giving beta-blockers within 8 hours of presentation with acute coronary syndrome (ACS) does not reduce in-hospital mortality, a meta-analysis has shown. Beta-blockers reduce…
NEW YORK (Reuters Health) – Thiazolidinediones (TZDs) are linked to an increased risk for extremity fractures in women over age 65, findings from a large retrospective cohort study…
NEW YORK (Reuters Health) – In patients with coronary shock and multivessel coronary disease, 30-day and 1-year mortality rates appear to be similar after percutaneous coronary intervention (PCI)…
NEW YORK (Reuters Health) – Cladribine and fingolimod, the first oral agents for multiple sclerosis (MS), significantly reduce relapse rates, risks of disability progression, and disease activity, according…
